Brilinta (ticagrelor) is a blood thinner that prevents clots after a heart attack or stroke, and its most common side effects are bleeding and shortness of breath. In the major clinical trial that led to its approval, about 7.7% of patients experienced notable bleeding events and nearly 14% developed some degree of shortness of breath. Most side effects are mild to moderate, but bleeding can occasionally be serious or life-threatening.
Bleeding: The Primary Risk
Brilinta works by making your blood less likely to clot, which is exactly why it protects against heart attacks but also why bleeding is the most significant side effect. The FDA’s prescribing information carries a boxed warning (the most serious type) about bleeding risk, stating that Brilinta “can cause significant, sometimes fatal bleeding.”
In the PLATO trial, which studied over 9,200 patients on Brilinta, the bleeding rates broke down like this:
- Major or minor bleeding: 7.7% of Brilinta patients, compared to 6.2% on the older blood thinner clopidogrel (Plavix)
- Major bleeding alone: 3.9% vs. 3.3% on clopidogrel
- Fatal or life-threatening bleeding: 1.9% vs. 1.6% on clopidogrel
- Fatal bleeding: 0.2% for both drugs
So Brilinta does carry a slightly higher bleeding risk than clopidogrel, though the absolute difference is small. A separate study in Korean patients found a larger gap: clinically significant bleeding occurred in 11.7% of ticagrelor patients versus 5.3% on clopidogrel over 12 months. The difference may partly reflect how different populations metabolize the drugs.
In practical terms, bleeding might show up as nosebleeds that take longer to stop, bruising more easily than usual, cuts that keep oozing, blood in your urine or stool, or unusually heavy periods. Dark or tarry stools, coughing up blood, or sudden severe headache with confusion can signal internal bleeding and need immediate attention.
Shortness of Breath
About 14% of patients on Brilinta in clinical trials developed dyspnea, or shortness of breath. That’s nearly double the rate seen with clopidogrel (7.8%). This side effect is distinctive to Brilinta and catches many patients off guard, especially since they’re often taking the drug after a heart event and may worry it means something is wrong with their heart.
The shortness of breath is usually mild to moderate. It often resolves on its own even while you continue taking the medication. In the PLATO trial, only 0.9% of patients stopped Brilinta because of it. In longer-term studies, the discontinuation rate was higher, reaching 4.3% to 6.9%, likely because patients on extended treatment had more time to become bothered by persistent symptoms.
Researchers initially believed the breathlessness happened because Brilinta slows the body’s ability to clear adenosine, a natural compound that affects breathing and heart rate. Higher adenosine levels could, in theory, trigger the sensation of needing more air. However, a follow-up study found that patients experiencing breathlessness on Brilinta didn’t actually have elevated adenosine in their blood. The true mechanism may involve a direct effect on nerve fibers that send breathing signals to the brain. Regardless of the cause, the breathlessness from Brilinta is not dangerous to your lungs or heart. If it becomes intolerable, your doctor can switch you to a different blood thinner.
The Aspirin Dose Rule
One of the more unusual aspects of Brilinta is that taking too much aspirin alongside it can actually make it less effective. The FDA warns that your daily aspirin dose should stay at or below 100 mg while you’re on Brilinta. This matters because many people are accustomed to taking a standard 325 mg aspirin tablet.
This issue came to light when researchers noticed that Brilinta performed worse in North American patients during the PLATO trial. After analyzing 36 possible explanations, they traced the problem to aspirin dosing: 53.6% of North American patients were taking high-dose aspirin alongside Brilinta, compared to just 1.7% in the rest of the world. The higher aspirin doses were blunting Brilinta’s ability to prevent clots. The FDA now requires a boxed warning about this, and your pharmacist or cardiologist should confirm you’re on a low-dose aspirin (typically 81 mg in the U.S.).
Other Common Side Effects
Beyond bleeding and breathlessness, some patients report headaches, dizziness, nausea, and diarrhea. These tend to be less frequent and milder than the two primary side effects. Elevated uric acid levels can also occur, which occasionally triggers gout in susceptible people. This likely ties back to the same adenosine pathway that may be responsible for the breathing issues.
Heart rhythm changes are another possibility. Brilinta can cause brief pauses in heartbeat, particularly during the first week of treatment. In most patients these pauses are short, produce no symptoms, and resolve without intervention. If you notice unusual dizziness, lightheadedness, or fainting spells, those are worth reporting.
What to Watch For
The most important thing to monitor while taking Brilinta is any sign of unusual or heavy bleeding. Small bruises and minor nosebleeds are common and usually manageable. What warrants urgency is bleeding you can’t stop, blood in your vomit or stool, sudden weakness on one side of your body, or a severe headache that comes on without warning, as these could indicate a serious bleed.
The FDA label also carries an important caution about stopping the drug: discontinuing Brilinta abruptly increases your risk of a heart attack or stroke. If you need to stop for any reason, including surgery, the timing should be planned with your cardiologist. For patients undergoing coronary artery bypass surgery, the recommendation is not to start Brilinta beforehand because surgical bleeding rates are already very high (over 80% of bypass patients experience major bleeding regardless of which blood thinner they’re on).